Lilly to Host Call Discussing Trial Design of New Solanezumab Phase 3 Study

Eli Lilly and Company

will host a conference call to discuss key elements of the trial design for EXPEDITION3, its third Phase 3 trial for solanezumab. Lilly's solanezumab is a monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease.  The conference call will be held from 9:00 a.m. to 9:45 a.m. EDT on Friday, July 12, 2013. A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at http://investor.lilly.com/events.cfm.  Subsequently, a replay of the presentation will be available on this same website.